Even Highly Curable Childhood Leukemias Take a Substantial Toll on Families, Study Finds
New research published by Rodwin et al in JNCCN—Journal of the National Comprehensive Cancer Network has found that families of children receiving treatment for B-cell acute lymphoblastic leukemia (ALL) experience substantial and lasting challenges beginning early after diagnosis, according to a multicenter study embedded in a Children’s Oncology Group (COG) trial. The COG includes more than 200 member institutions that treat about 80% of all new cases of childhood and adolescent cancer—therefore, these findings represent the experiences of most families.
ASCO 2026: Lung Cancer Specialist Apar Kishor Ganti, MD, Shares His Insights
The 2026 ASCO Annual Meeting featured numerous high-impact studies in lung cancer. To help readers identify the presentations with the greatest potential to influence clinical practice, The ASCO Post asked lung cancer specialist Apar Kishor Ganti, MD, MS, FASCO, to share his top picks. Dr. Ganti is Professor in the Division of Medical Oncology and holds the Dr. and Mrs. D. Leon University of Nebraska Medical Center (UNMC) Research Fund Chair in Internal Medicine at UNMC in Omaha.
Verifying the Seen and Unseen by AI in Cancer Imaging
Artificial intelligence (AI) can be used in medical imaging and diagnostics to enhance physician capabilities, but also to identify features that humans are not able to see. In research settings, AI has already demonstrated that ability to identify biomarkers from routine medical images and guide clinical decision-making, although few tools have been cleared for clinical use yet as issues of verifiability and other challenges remain.
Mocertatug Rezetecan (Mo-Rez) Shows Early Activity in Platinum-Resistant Ovarian and Endometrial Cancers
First results from the global phase I BEHOLD-1 study suggest that the investigational B7-H4–targeted antibody-drug conjugate mocertatug rezetecan showed activity in two difficult-to-treat gynecologic cancers: platinum-resistant ovarian cancer and recurrent or advanced endometrial cancer.1 At the highest doses evaluated, confirmed objective response rates were 62% in platinum-resistant ovarian cancer and 67% in endometrial cancer, with responses observed across a range of B7-H4 expression levels.
Study Supports Universal Germline Genetic Testing Regardless of Age at Cancer Diagnosis
Universal germline genetic testing after an individual receives a cancer diagnosis may help to uncover hereditary cancer risks in the patient's family, according to findings published in Cancer Discovery.
Charles Bennett and colleagues: The Inflation Reduction Act and Ibrutinib
Derek Raghavan: How I Discuss the Current Political Chaos When Patients Ask Health-Related Questions About It
Narjust Florez and Coral Olazagasti: Silence Is Complicity
Robert Peter Gale: Therapy With a TKI for EGFR-Variant Lung Adenocarcinoma: Lessons From CML?
Raj Mohan on Kindness, Mercy, Empathy, Compassion: Are They Relevant in the Era of Robotics and AI?
Sponsored Content
SPONSORED BY LILLY MEDICAL AFFAIRS
From Results to Action: Leveraging Multidisciplinary Teams to Optimize NSCLC Care
SPONSORED BY LILLY MEDICAL AFFAIRS
Targeting KRAS G12C in NSCLC: Shaping the Future Standard of CareMore Top Stories
Presidential Symposium Highlights in Small Cell Lung Cancer
Three phase III studies in small cell lung cancer (SCLC) were among the notable findings presented during a Presidential Symposium at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer held in Seoul. The studies addressed important questions...
FDA Approves Talazoparib With Enzalutamide for Certain Metastatic HRR-Mutated Prostate Cancers
Today, the U.S. Food and Drug Administration (FDA) approved the PARP inhibitor talazoparib (Talzenna) in combination with enzalutamide for the treatment of adults with metastatic androgen pathway modulation–naive or –sensitive (mAPMN/S) prostate cancer with homologous recombination repair (HRR)...
Three Decades of AYA Cancer Survivorship
Growing up, I was a curious, empathetic kid with an interest in biology. When I was diagnosed with non-Hodgkin lymphoma 2 months before I turned 15, those qualities shaped how I engaged with my care. I asked questions, wanted to understand what was happening in my body, and built strong...
Real-World Data Are Not Necessarily Real-World Evidence
KENNETH R. CARSON, MD, PhD THOMAS WILSON, PhD, DrPH CHARLES L. BENNETT, MD, PhD, MPP, MS (Law), FASCO Real-world data (RWD) provide raw material from which real-world evidence (RWE) is generated, but the two terms are not synonymous. Over the past decade, RWD and RWE have become...
GLP-1 RA Use Lower Among Adults With Both Diabetes and a History of Cancer
Adults with diabetes and a history of cancer were less likely to report current use of injectable glucagon-like peptide-1 receptor agonists (GLP-1 RAs) than those without a cancer history, despite having higher rates of cardiovascular and kidney disease. Olinto Linares-Perdomo, PhD, and colleagues...
Of Note in the Oncology Community: September/October 2026
Areej R. El-Jawahri, MD, FASCO, was named by ASCO as the 2026 recipient of the Joseph Simone Quality Care Award. She accepted her award and presented her keynote lecture at the 2026 ASCO Quality Care Symposium held recently in Boston. Dr. El-Jawahri is Co-Director of the Cancer Outcomes Research...
Omega-3 EPA Linked to Longer Survival After Surgery for Colorectal Cancer Liver Metastases
Patients assigned to receive high-dose eicosapentaenoic acid (EPA), an omega-3 fatty acid, before and after surgery for colorectal cancer liver metastases had longer overall survival than those assigned to receive placebo, according to results of the phase III EMT2 trial presented at the European...
